For the next Company Snapshot for the BIO Investor Forum, we’ve spoken with one of the presenting companies at the event, Profil Institute for Translational Medicine, Inc. To find out more about this organization and what they’re doing for biotech, please read below! You’ll be able to see their presentation onsite, Wednesday 10/10 at 9:30am in the Presidio Room.
What is your company’s lead product or technology?
Based on collaborations with biopharma, drug discovery companies and academia, we are building a pipeline of metabolic compounds to address two of today’s fastest growing epidemics: diabetes and obesity. Our preliminary pipeline includes an intranasal insulin delivery platform and non-temperature-sensitive insulin injectable, in addition to GPR119 and GPR40 compounds. We employ the methodologies and proprietary technology of our parent company, Profil Institute for Clinical Research, Inc., a center of excellence for early phase clinical research for metabolic diseases, to progress the compounds from preclinical through early stage clinical trials. Once proof of concept is validated and a conclusive data package is generated, the compounds can be licensed to clients in the pharmaceutical industry.
How does your company go about differentiating itself from the competition?
Virtual pharma companies investigating early phase compounds generally need to outsource or build the infrastructure to complete preclinical and early phase trials and in many cases have a team of people employed to scout for new leads. However, Profil Institute for Translational Medicine leverages its parent company’s spectrum of scientific clinical research methods and disease-specific expertise. One advantage is the company’s existing relationships with pharma and biopharma for access to promising metabolic leads. However, more importantly is the company’s ability to process compounds faster and more efficiently while also seeking to generate higher quality and conclusive data about a drug candidate.
What are the short-term and long-term priorities for your company?
Near-term we will complete proof of concept studies of the insulin intranasal platform and injectable compound under investigation and work on licensing these compounds, providing near-term liquidity for any potential investors.
Long-term we will continue to build our pipeline of metabolic compounds for licensing, which hopefully will result in better treatments for diabetes, obesity and cardiometabolic diseases.
Tell us something about your company that investors might not know.
Close to 50% of the top pharma’s pipelines are derived from in-licensing compounds, yet inconclusive or ambiguous data can lead to redundant trials and unnecessary spending. Profil Institute for Translational Medicine is in a unique position to generate more accurate and conclusive proof of concept data by leveraging the disease-specific expertise and advanced methodologies of its parent company. For investors, the company’s ability to quickly filter through leads, validate compounds more efficiently and generate better data for a higher valuation at licensing can mean a faster and more lucrative ROI.
We look forward to seeing Profile Institute for Translational Medicine onsite at the Investor Forum next week, and don’t forget to schedule meetings with them!